Predictive Technology Group, Inc. (PRED)
| Market Cap | 30.24M |
| Revenue (ttm) | 21.27M |
| Net Income (ttm) | -93.36M |
| Shares Out | 299.60M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $0.140 |
| Previous Close | $0.140 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.000 - 0.000 |
| Day's Volume | 0 |
| 52-Week Range | 0.061 - 1.380 |
News
Shares of two companies that a short seller alleged were making fraudulent claims about tests for COVID-19 were suspended from trading by the Securities and Exchange Commission on Wednesday, a...
About PRED
Predictive Technology Group, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; an... [Read more...]
| Industry Research and Development in Biotechnology | Founded 2005 |
| CEO Bradley C. Robinson | Employees 62 |
| Stock Exchange OTCMKTS | Ticker Symbol PRED |
Financial Performance
In 2020, PRED's revenue was $24.44 million, a decrease of -43.80% compared to the previous year's $43.49 million. Losses were -$85.90 million, 456.9% more than in 2019.